Abstract:Introduction: Owing to the limited treatment options for hepatocellular carcinoma (HCC), interventions targeting pre-HCC stages have attracted increasing attention. In the pre-HCC stage, hepatic tumor-initiating cells (hTICs) proliferate abnormally and contribute to hepatocarcinogenesis. Numerous studies have investigated targeted senescence induction as an HCC intervention. However, it remains to be clarified whether senescence induction of hTICs could serve as a pre-HCC intervention. Objectives: This study was designed to investigate whether senescence induction of hTICs in the precancerous stage inhibit HCC initiation. Methods and results: HCC models developed from chronic liver injury (CLI) were established by using Fah-/- mice and N-Ras + AKT mice. PD-0332991, a selective CDK4/6 inhibitor that blocks the G1/S transition in proliferating cells, was used to induce senescence during the pre-HCC stage. Upon administration of PD-0332991, we observed a significant reduction in HCC incidence following selective senescence induction in hTICs, and an alleviation liver injury in the CLI-HCC models. PD-0332991 also induced senescence in vitro in cultured hTICs isolated from CLI-HCC models. Moreover, RNA sequencing (RNA-seq) analysis delineated that the "Cyclin D-CDK4/6-INK4-Rb" pathway was activated in both mouse and human liver samples during the pre-HCC stage, while PD-0332991 exhibited substantial inhibition of this pathway, thereby inducing cellular senescence in hTICs. Regarding the immune microenvironment, we demonstrated that senescent hTICs secrete key senescence-associated secretory phenotypic (SASP) factors, CXCL10 and CCL2, to activate and recruit macrophages, and contribute to immune surveillance. Conclusion: We found that hTICs can be targeted and induced into a senescent state during the pre-HCC stage. The SASP factors released by senescent hTICs further activate the immune response, facilitating the clearance of hTICs, and consequently suppressing HCC occurrence. We highlight the importance of pre-HCC interventions and propose that senescence-inducing drugs hold promise for preventing HCC initiation under CLI.

EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A

TRAF2 Inhibits Senescence in Hepatocellular Carcinoma Cells Via Regulating the ROMO1/ NAD+/SIRT3/SOD2 Axis.

Silencing of Hsa_circ_0008450 Represses Hepatocellular Carcinoma Progression Through Regulation of Microrna-214-3p/ezh2 Axis

Abstract 4881: Polycomb Protein EZH2 Activates Wnt/β-catenin Signaling to Promote Hepatocellular Carcinoma Development

Identification of Prognostic miRNAs Targeting EZH2 in Hepatocellular Carcinoma Using The Cancer Genome Atlas Database

MicroRNA Let-7C-5p Alleviates in Hepatocellular Carcinoma by Targeting Enhancer of Zeste Homolog 2: A Study Intersecting Bioinformatic Analysis and Validated Experiments

Dual Inhibition of H3K9me2 and H3K27me3 Promotes Tumor Cell Senescence without Triggering the Secretion of SASP

Tackling Cellular Senescence by Targeting Mirnas

Repression of YEATS2 induces cellular senescence in hepatocellular carcinoma and inhibits tumor growth

CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells

EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.

Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma

Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Identification of immunosenescence of unconventional T cells in hepatocellular carcinoma

SEH1L siliencing induces ferroptosis and suppresses hepatocellular carcinoma progression via ATF3/HMOX1/GPX4 axis

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma

Exosomal miRNA-146a-5p Derived from Senescent Hepatocellular Carcinoma Cells Promotes Aging and Inhibits Aerobic Glycolysis in Liver Cells via Targeting IRF7

Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma

Sorafenib Suppresses Growth and Survival of Hepatoma Cells by Accelerating Degradation of Enhancer of Zeste Homolog 2